Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders
Abstract The therapeutic effects of mesenchymal stromal/stem cells (MSCs) are mainly based on three characteristics: immunomodulation, tissue regeneration, and hematopoietic support. Cell therapy using culture-expanded MSCs is effective in some intractable bone and hemato-immune disorders; however,...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-04-01
|
Series: | Inflammation and Regeneration |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s41232-017-0038-5 |
id |
doaj-fd7fe3adfd114dd5ae933a75787de19c |
---|---|
record_format |
Article |
spelling |
doaj-fd7fe3adfd114dd5ae933a75787de19c2020-11-25T00:47:36ZengBMCInflammation and Regeneration1880-81902017-04-013711710.1186/s41232-017-0038-5Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disordersNoriko Sugino0Tatsuo Ichinohe1Akifumi Takaori-Kondo2Taira Maekawa3Yasuo Miura4Department of Transfusion Medicine and Cell Therapy, Kyoto University HospitalDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima UniversityDepartment of Hematology/Oncology, Graduate School of Medicine, Kyoto UniversityDepartment of Transfusion Medicine and Cell Therapy, Kyoto University HospitalDepartment of Transfusion Medicine and Cell Therapy, Kyoto University HospitalAbstract The therapeutic effects of mesenchymal stromal/stem cells (MSCs) are mainly based on three characteristics: immunomodulation, tissue regeneration, and hematopoietic support. Cell therapy using culture-expanded MSCs is effective in some intractable bone and hemato-immune disorders; however, its efficacy is limited. In this article, we review the previous efforts to improve the clinical outcomes of cell therapy using MSCs for such disorders. We describe pharmacological targeting of endogenous bone marrow-derived MSCs as a crucial quality-based intervention to establish more effective MSC-based therapies.http://link.springer.com/article/10.1186/s41232-017-0038-5Mesenchymal stromal/stem cellHematopoiesisRegenerationImmunomodulationPharmacological modificationCell therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Noriko Sugino Tatsuo Ichinohe Akifumi Takaori-Kondo Taira Maekawa Yasuo Miura |
spellingShingle |
Noriko Sugino Tatsuo Ichinohe Akifumi Takaori-Kondo Taira Maekawa Yasuo Miura Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders Inflammation and Regeneration Mesenchymal stromal/stem cell Hematopoiesis Regeneration Immunomodulation Pharmacological modification Cell therapy |
author_facet |
Noriko Sugino Tatsuo Ichinohe Akifumi Takaori-Kondo Taira Maekawa Yasuo Miura |
author_sort |
Noriko Sugino |
title |
Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders |
title_short |
Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders |
title_full |
Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders |
title_fullStr |
Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders |
title_full_unstemmed |
Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders |
title_sort |
pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders |
publisher |
BMC |
series |
Inflammation and Regeneration |
issn |
1880-8190 |
publishDate |
2017-04-01 |
description |
Abstract The therapeutic effects of mesenchymal stromal/stem cells (MSCs) are mainly based on three characteristics: immunomodulation, tissue regeneration, and hematopoietic support. Cell therapy using culture-expanded MSCs is effective in some intractable bone and hemato-immune disorders; however, its efficacy is limited. In this article, we review the previous efforts to improve the clinical outcomes of cell therapy using MSCs for such disorders. We describe pharmacological targeting of endogenous bone marrow-derived MSCs as a crucial quality-based intervention to establish more effective MSC-based therapies. |
topic |
Mesenchymal stromal/stem cell Hematopoiesis Regeneration Immunomodulation Pharmacological modification Cell therapy |
url |
http://link.springer.com/article/10.1186/s41232-017-0038-5 |
work_keys_str_mv |
AT norikosugino pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders AT tatsuoichinohe pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders AT akifumitakaorikondo pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders AT tairamaekawa pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders AT yasuomiura pharmacologicaltargetingofbonemarrowmesenchymalstromalstemcellsforthetreatmentofhematologicaldisorders |
_version_ |
1725259581675798528 |